Common Contracts
8 similar Common Stock Purchase Warrant contracts by Brainstorm Cell Therapeutics Inc, Catabasis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANTCommon Stock Purchase Warrant • May 13th, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that [ ], or [his/her] registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the closing date of the Company’s Qualified Financing (as defined below) and on or before 5:00 p.m. (Eastern Standard Time) on the sixth anniversary of the closing date of the Company’s Qualified Financing, that number of shares of Common Stock, $0.001 par value per share, of the Company (the “Common Stock”) equal to the quotient of (A) $[ ], divided by (B) the Qualified Financing Purchase Price (as defined below). This Warrant shall be exercisable for a purchase price per share equal to the fair market value of the Common Stock at the time of the closing of the Qualified Financing. The shares purchasable upon exercise of this Warrant, and the purchase price per share, ea
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANTCommon Stock Purchase Warrant • March 5th, 2015 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that [ ], or [his/her] registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the closing date of the Company’s Qualified Financing (as defined below) and on or before 5:00 p.m. (Eastern Standard Time) on the sixth anniversary of the closing date of the Company’s Qualified Financing, that number of shares of Common Stock, $0.001 par value per share, of the Company (the “Common Stock”) equal to the quotient of (A) $[ ], divided by (B) the Qualified Financing Purchase Price (as defined below). This Warrant shall be exercisable for a purchase price per share equal to the fair market value of the Common Stock at the time of the closing of the Qualified Financing. The shares purchasable upon exercise of this Warrant, and the purchase price per share, ea
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • September 4th, 2012 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANTCommon Stock Purchase Warrant • September 4th, 2012 • Intercept Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 4 OF THIS WARRANTCommon Stock Purchase Warrant • August 15th, 2011 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
